Medtech companies urge US FDA to enhance, not replace, 510(k) process
This article was originally published in SRA
Executive Summary
US medtech industry association AdvaMed has reiterated its concerns over a report by the Institute of Medicine earlier this year that urged the Food and Drug Administration to replace its 510(k) review programme for clearing low- and medium-risk devices with a completely new regulatory process1,2.